The results, presented by Michael Chuong, M.D., medical director of radiation oncology at the Miami Cancer Institute, part of Baptist Health South Florida, demonstrated improvement in overall survival and quality of life. Findings showed longer median survival of 26 months compared to 12-15 months typically seen in patients receiving chemotherapy and standard radiation therapy. The 2-year overall survival was over 50 percent, which is more than double the expected 2-year rate of 20 percent with lower dose radiation.

In related news

ViewRay’s 510(k) pending submission consists of features including new MRI imaging sequences, automated workflow steps, on-table auto-contouring tools, multi-planar tissue tracking and automated beam gating, and the ability for clinicians to work collaboratively during patient treatments. The submission also includes a new brain treatment package and the integration of a real-time patient feedback display.

“We are pleased to announce this significant milestone in our development roadmap. ViewRay continues to be the leading innovator of MR-guided radiation therapy by now offering a new suite of features including multi-planar tissue tracking which enhances our industry-unique automatic beam gating technology”, said Scott Drake, ViewRay president and CEO, “As the number of MRIdian programs expands globally, customers have reinforced that they desire faster treatment times and expanding MRIdian treatments to additional disease sites. The technology submitted in our 510(k) is intended to address these customer requests.”

In related news

The meeting will feature presentations that showcase the MRIdian system, including how clinicians use this cutting-edge Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) technology to tackle both tough-to-treat and ubiquitous cancer, expand the clinical experience with the device, and impact patient outcomes.

The MRIdian system at Providence Portland Medical Center is part of The Elsie Franz Finley Radiation Oncology Center and Providence Cancer Institute. MRIdian utilizes on-table soft tissue imaging to allow oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that is unavailable with conventional image-guided radiation therapy (IGRT) technologies.

UF startup ViewRay, Inc. MRIdian machine allows doctors to attack tumors with precision in real-time, giving patients with inoperable cancers new hope. ViewRay, Inc. is a leading medical technology company that provides groundbreaking MRI-guided radiation therapy. Doctors call it breakthrough technology, making it clear that the ViewRay MRIdian is only used for certain cases based on the type of cancer and position of the tumor.

The new upgradable capabilities enhance the features of MRIdian’s SmartVISION MRI (magnetic resonance imaging), including:

• Expanded high-definition visualization and enhanced contrast between different tissues, to assist clinicians with tissue visualization and beam contouring;
• The potential to aid in the assessment and prediction of tumor response to radiation therapy is enabled by “DWI”, a diffusion weighted imaging feature that tracks treatment progress by distinguishing between tumor and normal tissues;
• Faster, brighter, more detailed anatomical planar imaging to strike tumors with greater precision and accuracy through proprietary technology, which allows for a 2X increase in MRI speed (to 8 frames per second), a 2X increase in image resolution, and a 2X improvement in MR signal-to-noise ratio (SNR); and
• Potential reduction in treatment delivery time through enhanced multileaf collimator (MLC) speed.

Deployed within the GenesisCare network, the first two systems will offer oncologists the ability to leverage soft-tissue imaging for the visualization of tumors, personalizing treatment with greater accuracy in the delivery of high-quality, image-guided, adaptive radiotherapy.

Learn more about ViewRay to Supply UK’s GenesisCare With Country’s First MRIdian Systems.